TNF and cancer: In a study of 222 first-line ICI-treated melanoma patients with grade 3 or higher irAEs, we found a shorter overall survival and cancer-related survival in patients treated with TNF inhibition as second-line immunosuppressant compared to patients who only required corticosteroid treatment.